Cooksley Catherine D, Avritscher Elenir B C, Bekele Benjamin N, Rolston Kenneth V, Geraci Jane M, Elting Linda S
Section of Health Services Research, Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Cancer. 2005 Aug 1;104(3):618-28. doi: 10.1002/cncr.21203.
Although patients with cancer generally respond favorably to vaccination, they may not receive annual influenza vaccinations. The current population-based study described the epidemiology and outcomes of potentially preventable, serious influenza-related infections in patients with cancer.
From the Nationwide Inpatient Sample, the authors created a subsample that included discharges with any International Classification of Diseases, ninth revision, diagnosis code for cancer and principal diagnosis code for influenza, bronchopneumonia, or pneumonia caused by an unspecified organism. From the latter two diagnosis codes, the authors estimated excess cases during the influenza season for each year and stratum, then selected a random sample from fall and winter discharges. Subset analyses included weighted sample means, frequencies, and analysis of variance values. The authors converted charges to costs using cost-to-charge ratios and inflated these to 2003 U.S. dollars. Hospitalization and mortality rates were calculated using 5-year cancer prevalence estimates.
The estimated mean annual hospital discharges of patients with cancer with potentially preventable, serious influenza-related infections numbered 16,000. The average length and cost per stay were 6 days and > USD 6300, respectively. Approximately 9% of patients died in the hospital and 31% needed further skilled care. The estimated age-specific rates for hospitalization and death per 100,000 in the prevalent cancer population were 219 and 17.4, respectively, for patients age < 65 years and 623 and 59.4, respectively, for those age > or = 65 years. Hospitalization costs averaged USD 1300 more for patients age < 65 years.
Death from influenza-related infections occurred in an estimated 9% of patients with cancer hospitalized for such. Using recommended vaccination schedules for patients with cancer and their contacts reduced hospitalizations, treatment delays, and deaths in this highly susceptible population.
尽管癌症患者通常对疫苗接种反应良好,但他们可能未接种年度流感疫苗。当前这项基于人群的研究描述了癌症患者中潜在可预防的、严重的流感相关感染的流行病学情况及结局。
作者从全国住院患者样本中创建了一个子样本,其中包括任何国际疾病分类第九版中诊断代码为癌症以及主要诊断代码为流感、支气管肺炎或由未明确病原体引起的肺炎的出院病例。根据后两个诊断代码,作者估算了每年和每个分层在流感季节的超额病例数,然后从秋冬季节的出院病例中选取随机样本。亚组分析包括加权样本均值、频率和方差分析值。作者使用成本收费比将费用转换为成本,并将其换算为2003年的美元价值。住院率和死亡率使用5年癌症患病率估计值进行计算。
估计每年因潜在可预防的、严重的流感相关感染而住院的癌症患者平均出院人数为16000例。每次住院的平均时长和费用分别为6天和超过6300美元。约9%的患者在医院死亡,31%的患者需要进一步的专业护理。在癌症现患人群中,估计每10万人中<65岁患者的住院率和死亡率分别为219和17.4,≥65岁患者分别为623和59.4。<65岁患者的住院费用平均高出1300美元。
估计9%因流感相关感染住院的癌症患者死亡。对癌症患者及其接触者采用推荐的疫苗接种计划可减少这一高度易感人群的住院率、治疗延误和死亡。